Tonix Pharma Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the…
Tonix Pharmaceuticals Holding Corp. announced an exclusive agreement to in-license a triple reuptake inhibitor (TRI), TNX-1600 (formerly D-578), to treat posttraumatic stress disorder…
Read More...
Read More...
